Abstracts tagged "Cardiovascular disease"

Abstract Number: 569 • 2013 ACR/ARHP Annual Meeting
Hydroxycholorquine Is Cardioprotective In Neonatal Rat Cardiomyocytes Exposed To Simulated Myocardial Ischaemic/Reperfusion Injury.-An Effect Mediated Through ERK Phosphorylation
Lauren Bourke¹, James McCormick², Anastasis Stephanou³ and Yiannis Ioannou⁴, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Clinical & Molecular Genetics Unit, University College London, London, United Kingdom, ³MMBU, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom
Background/Purpose: A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage which is known as ischaemic reperfusion (I/R) injury…
Abstract Number: 372 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk In Intensively Treated Rheumatoid Arthritis: Comparison To An Osteoarthritis Population. First Prospective Analysis Of The ACT-CVD Cohort
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality. This association is thought to be due to the chronic inflammatory disease…
Abstract Number: 2897 • 2013 ACR/ARHP Annual Meeting
The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Eric C. Sayre², Diane Lacaille^1,3 and John M. Esdaile⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Previous hospital-based studies have shown that patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease, but limited population-based data are…
Abstract Number: 1814 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Iman Hemmati², Eric C. Sayre³, Kamran Shojania^3,4 and Hyon Choi^3,5,6, ¹Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Data on the risk of pulmonary embolism (PE) and deep venous thrombosis (DVT) in patients with systemic sclerosis (SSc) is lacking. To fill this…
Abstract Number: 959 • 2013 ACR/ARHP Annual Meeting
Interleukin 10 Negatively Correlates With Glycoprotein VI-Related Platelet Activation In Rheumatoid Arthritis (RA): A Novel Potential Target Of Cardiovascular Morbidity In RA
Leann Bell¹, Anne M. Madigan¹, Paul A. MacMullan¹, Eimear Dunne², Paola M. Bagaglia¹, Laura J. Durcan¹, Dermot Kenny² and Geraldine M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland
Background/Purpose: Patients with rheumatoid arthritis (RA) die prematurely of cardiovascular disease (CVD). Platelet mediated thrombosis is a major cause of CVD. Platelets amplify inflammation in RA via the collagen receptor,…
Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Jaime Calvo-Alén¹, Carmela Baamonde², Ignacio Villa¹, Víctor Martínez-Taboada³, Mario Agudo⁴ and Juan Gómez-Gerique⁵, ¹Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ²Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
Abstract Number: 377 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Stroke In Patients With Rheumatoid Arthritis
Anja Strangfeld¹, Yvette Meißner², Adrian Richter³, Matthias Schneider⁴, Hans Peter Tony⁵, Kerstin Gerhold⁶, Angela Zink⁷ and Joachim Listing³, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center Berlin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Department of Endocrinology, Diabetes and Rheumatology, University of Duesseldorf, Duesseldorf, Germany, ⁵Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁶Programme Area of Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of stroke. This event is associated with considerable sequelae and might result in death or…
Abstract Number: 2825 • 2013 ACR/ARHP Annual Meeting
The Influence Of Early Menopause On Cardiovascular Risk In Women With Rheumatoid Arthritis
Emily Pfeifer¹, Cynthia S. Crowson², Shreyasee Amin³, Sherine E. Gabriel⁴ and Eric L. Matteson⁵, ¹Department of Medicine, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Lifetime exposure to female sex hormones may play a role in the development and severity of rheumatoid arthritis (RA). These same hormones have also…
Abstract Number: 1749 • 2013 ACR/ARHP Annual Meeting
Treatment Strategies and Outcomes In Patients With Systemic Sclerosis and Acute Myocardial Infarction
Priya Prakash¹, Dhaval Kolte¹, Sahil Khera¹, Jagadish Khanagavi¹, Marjan Mujib², Chandrasekar Palaniswamy³, Farrah Gutwein⁴, Sachin Sule¹, Wilbert S. Aronow³, William H. Frishman³ and Julia Ash⁴, ¹Medicine, New York Medical College, Valhalla, NY, ²Internal Medicine, New York Medical College, Valhalla, NY, ³Cardiology, New York Medical College, Valhalla, NY, ⁴Rheumatology, New York Medical College, Valhalla, NY
Background/Purpose: , Systemic Sclerosis (SSc) is associated with an increased risk of cardiovascular diseases, including acute myocardial infarction (AMI). However, whether SSc influences treatment choice and…
Abstract Number: 895 • 2013 ACR/ARHP Annual Meeting
The Relative Risk Of Aortic Aneurysm In Patients With Giant Cell Arteritis Compared With The General Population
Joanna Robson¹, Amit Kiran², Joseph Maskell³, Andrew Hutchings⁴, Nigel K. Arden⁵, Bhaskar Dasgupta⁶, William Hamilton⁷, Akan Emin⁸, David Culliford³ and Raashid A. Luqmani², ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Faculty of Medicine, University of Southampton, Southampton, United Kingdom, ⁴Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁵NDORMS; MRC Lifecourse Epidemiology Unit, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ⁷Primary Care Diagnostics, University of Exeter Medical School, Exeter, United Kingdom, ⁸Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom
Background/Purpose: To evaluate the risk of aortic aneurysm in patients with giant cell arteritis (GCA) when compared with age, gender and location matched controls from…
Abstract Number: 470 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Relationship Between Inflammation Suppression and Changes In Cholesterol Levels
Christina Charles-Schoeman¹, Steven P. Weinstein², Janet van Adelsberg³, Tanya Momtahen⁴, Richard Wu⁵, Neil Graham⁶ and Stefano Fiore⁷, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁴Program Direction, Sanofi, Bridgewater, NJ, ⁵BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Clinical Science, Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab (SAR) is a fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα) which is currently being evaluated for…
Abstract Number: 358 • 2013 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Carotid Plaque Progression and Subsequent Cardiovascular Events In Rheumatoid Arthritis: The 2-Year Prospective Cohort Study
Churl Hyun Im¹, Sang Hoon Kwon², Jeong Soo Eun¹, Na Ri Kim¹, Eon Jeong Nam¹ and Young Mo Kang³, ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Internal medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ³Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Rheumatoid arthritis (RA) patients have increased prevalence of carotid atherosclerosis, especially plaque formation, which has been associated with inflammatory burden in a previous study.…
Abstract Number: 2826 • 2013 ACR/ARHP Annual Meeting
Performance Of Five Current Risk Algorithms In Predicting Cardiovascular Events In Rheumatoid Arthritis Patients
Elke.E.A. Arts¹, Calin Popa¹, Alfons A. den Broeder², Anne G. Semb³, Tracey Toms⁴, George Kitas⁴, Piet L.C.M. van Riel¹ and Jaap Fransen⁵, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom, ⁵Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Cardiovascular risk in rheumatoid arthritis (RA) is increased. The cardiovascular (CV) risk algorithms used in the general population may underestimate the risk of cardiovascular…
Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Elana J. Bernstein¹, Jessica K. Gordon², Wei-Ti Huang³ and Virginia D. Steen⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
Abstract Number: 887 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez¹, Mª Angeles Aguirre², Nuria Barbarroja¹, Tomás Cerdó-Ráez³, Maria Laura Bertolaccini⁴, Munther A. Khamashta⁵, Antonio Rodriguez-Ariza⁶, Yolanda Almaden⁷, Husam Khraiwesh⁸, Jose Antonio Gonzalez-Reyes⁹, Jose Manuel Villalba¹⁰, Eduardo Collantes¹¹ and Mª Jose Cuadrado¹², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Imibic, Córdoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁷Imibic, Códoba, Spain, ⁸UCO, Córdoba, Spain, ⁹Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ¹⁰Cell Biology, Physiology and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ¹¹Rheumatology, Hospital Reina Sofia, Cordoba, Spain, ¹²Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced systemic lupus erythematosus (SLE). Although there is evidence that statins have anti-inflammatory properties, their mechanism of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.